Summary
Other Scenarios:
- GSK - NVS
- GSK - SNY
- NVS - ACAMY
- SNY - ACAMY
| Buyer: | GlaxoSmithKline plc (ADR) (GSK) | Last Price: | 45.33 | Market Cap.: | 122.74B |
|---|---|---|---|---|---|
| Target: | Acambis plc (ADR) (ACAMY) | Last Price: | 3.70 | Market Cap.: | 199.19M |
Lines of Business Summary:
- GlaxoSmithKline plc (ADR) (GSK) competes in 1 industry and 222 product/service groups
- Acambis plc (ADR) (ACAMY) competes in 1 industry and 4 product/service groups
- A combined entity will have 0% Product/Service Group overlap
- GlaxoSmithKline plc (ADR) (GSK) has 17 and Acambis plc (ADR) (ACAMY) has 0 suppliers that rely on a material % of their business. They share 0 in common.
Product Summary:
Overlap & Complementary Sectors
| Sector | Buyer | Target | # of Focused Companies |
|---|---|---|---|
Healthcare |
|
|
893 |
Biopharmaceuticals |
|
|
366 |
|
Medical Devices |
|
241 | |
|
Nutritional Health |
|
25 | |
|
Outsourced Services |
|
66 | |
|
Scientific Products |
|
35 |
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Sample Products in Similar Lines of Business |
Sample Products in Complementary Lines of Business |
||
Buyer (Total: 251)
|
Target (Total: 6)
|
Buyer
|
Targetn/a |
Business Relationship Summary:
Top Key Suppliers |
Top Key Customers |
||
Buyer (Total: 67)
|
Target (Total: 5)
|
Buyer (Total: 25)
|
Target (Total: 2)
|
Key Financial Summary:
Key Metrics
| Buyer | Target | |
|---|---|---|
| Number of Employees | 103,483 | 285 |
| Revenue Per Employee | 461,819.2 | 78,593.9 |
| Total Revenue | 11,914.9 | 5.5 |
| Total Expenses | 8,747.7 | -3.4 |
Other Revenue
|
0.0 | 0.0 |
|
Cost of Revenue
|
3,268.9 | 4.5 |
|
SG&A Expense
|
3,635.9 | 5.5 |
|
Research & Development
|
2,080.2 | 15.2 |
|
Other Operating Expense
|
-237.3 | -28.7 |
|
Operating Income
|
3,167.2 | 8.9 |
|
Unusual Income
|
0.0 | 0.0 |
|
LT Debt to Capital
|
42.39 | 2.01 |
|
Fwd P/E
|
11.47 | n/a |
|
Fwd P/Rev
|
2.67 | n/a |
| Book Value | 19,152.8 | 125.6 |
|
Curr Portion of LTD/Cap Lease
|
0.0 | 0.0 |
Individual Company Summary
Focused
Buyer
Focused ():
Healthcare > Biopharmaceuticals
Target
Focused ():
Healthcare > Biopharmaceuticals > Infectious Diseases > Viral > Vaccines
Business Description
Buyer
GlaxoSmithKline plc (GSK) is a global healthcare group engaged in the creation, discovery, development, manufacture and marketing of pharmaceutical and consumer health-related products. It has and operations in some 114 countries, with products sold in over 140 countries. The Company operates in two segments: Pharmaceuticals (prescription pharmaceuticals and vaccines), and Consumer Healthcare (over-the-counter medicines, oral care and nutritional healthcare). The markets for its products are the United States, France, Japan, United Kingdom, Italy, Germany and Spain.
Target
Acambis plc is a biopharmaceutical company operating in the infectious disease arena, with a focus on developing new vaccines. The Company supplied smallpox vaccines to more governments than any other company. To maximize the revenues from its smallpox franchise, the Company is now targeting two principal opportunities: ACAM2000 warm-base manufacturing for the United States Government and supply of MVA3000 to the United States Government. Warm-base manufacturing would produce doses of ACAM2000 each year for the Strategic National Stockpile. Together with its partner, Baxter International Inc., the Company is bidding for a major contract to supply the United States Government with doses of its MVA3000 attenuated smallpox vaccine. This vaccine is for the proportion of the population who could suffer adverse reactions to smallpox vaccines, such as ACAM2000. In October 2006, Acambis sold its Berna Products Corporation business to Crucell N.V.
Deal Summary
Key Ratios
| Buyer | Target | |
|---|---|---|
|
Gross Margin %
|
76.59 | 38.07 |
|
Operating Margin %
|
33.43 | -66.49 |
|
Quick Ratio
|
1.02 | 2.68 |
|
Current Ratio
|
1.32 | 2.88 |
|
Coverage Ratio
|
-0.02 | -0.06 |
| Total Assets | 61,834.1 | 165.7 |
| Return on Equity % | 55.3 | -40 |
| Return on Assets % | 17.13 | -30.31 |
|
Cash+ ST Inv. Per Share
|
3.69 | 1.66 |
| Total Debt | 21,083.4 | 18.2 |
| Total Debt to Equity % | 110.08 | 14.49 |
| Total Debt to Tangible Equity % | 279.88 | 18.29 |
|
Debt to Asset %
|
34.10 | 10.98 |
Product Summary
| Sector | Buyer | Target |
|---|---|---|
|
Healthcare |
|
|
Biopharmaceuticals |
|
|
|
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
|
|
|
|
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
|
|
|
|
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
|
|
|
|
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
|
|
|
|
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
|
|
|
|
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
|
|
|
|
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
|
|
|
|
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
|
|
|
|
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
|
|
|
|
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
|
|
|
|
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
|
|
|
|
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
|
|
|
|
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
|
|
|
|
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
|
|
|
|
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
|
|
|
|
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
|
|
|
|
Toxicology
The Toxicology Subsector includes therapeutics that treat harmful effects from exposure to toxic substances; narcotics, nicotine and alcohol withdrawal therapeutics are also included in this sector.
|
|
|
|
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
|
|
|
|
Weight Management
The Weight Management Subsectors includes herapeutics that treat and manage weight disorders.
|
|
|
|
Medical Devices |
|
|
|
Clinical Diagnostics
The Clinical Diagnostics Subsector includes medical devices that analyze human body specimens within a medical setting. These devices, including equipment, biological and chemical reagents are primarily used for the diagnosis of diseases.
|
|
|
|
Drug Delivery
The Drug Delivery Subsector includes medical devices that facilitate the delivery of medications through different anatomical entryways, including blood vessels, skin, the mouth, and the lungs. Common devices in this sector include vascular access catheters, needles, implants, and inhalers.
|
|
|
|
Respiratory
The Respiratory Subsector includes medical devices that diagnose and treat respiratory diseases.
|
|
|
|
Nutritional Health |
|
|
|
Dietary/Naturopathic Supplements
The Dietary/Naturopathic Subsector includes nutritional biochemicals and nutrients derived from natural sources that are intended to support health.
|
|
|
|
Outsourced Services |
|
|
|
Development/Manufacturing Services
The Development/Manufacturing Services Subsector includes companies that provide research, development, manufacturing, sales and marketing to biopharmaceutical and medical device companies.
|
|
|
|
Scientific Products |
|
|
|
Consumables
The Consumables Subsector includes chemicals, reagents, standards, media, and disposable labware that are normally depleted or worn out by continuous use.
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Product Details
| Sector | Buyer | Target |
|---|---|---|
|
Healthcare |
|
|
|
Biopharmaceuticals |
|
|
Allergies |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for treatment of allergic reactions in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
Upper Respiratory |
|
|
|
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
|
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.
Buyer Products:
|
|
|
|
Antihistamines/Decongestants/Analgesics/Antipyretics
Therapeutics that treat allergic reactions by suppressing inflammation, reducing mucous build up, relieving pain, and reducing fever.
Buyer Products:
|
|
|
|
Antihistamines/Decongestants/Antitussives/Analgesics/Antipyretics
Therapeutics that treat allergic reactions by suppressing inflammation, reducing mucous build up, relieving or preventing coughs, relieving pain, and reducing fever.
Buyer Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation using a steroidal compound.
Buyer Products:
|
|
|
|
Cardiovascular System |
|
|
|
Heart Disorders |
|
|
|
Acute Coronary Syndrome (ACS) |
|
|
|
Anticoagulating Agents |
|
|
|
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.
Buyer Products:
|
|
|
|
Arrhythmia |
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium into heart muscle cells.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents/Potassium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium and potassium into heart muscle cells.
Buyer Products:
|
|
|
|
Heart Failure (HF) |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat the ineffective pumping of the heart by blocking beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of water and sodium, but not potassium in urine.
Buyer Products:
|
|
|
|
Recombinant B-Type Natriuretic Peptides (BNP)
Therapeutics that treat the ineffective pumping of the heart by increasing the excretion of sodium and water in urine.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents/Potassium Channel Blocking Agents
Therapeutics that treat the ineffective pumping of the heart by preventing the entry of sodium or potassium into heart muscle cells.
Buyer Products:
|
|
|
|
Myocardial Infarction (MI) |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat irreversible damage to the heart muscle by blocking the beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Vascular Disorders |
|
|
|
Deep Vein Thrombosis (DVT) |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Thrombin Inhibitors
Therapeutics that prevent or treat clots in blood vessels by preventing blood clots from forming.
Buyer Products:
|
|
|
|
Hypertension |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of water and sodium, but not potassium in urine.
Buyer Products:
|
|
|
|
Primary Pulmonary Hypertension |
|
|
|
Prostacyclins
Therapeutics that relieve pulmonary hypertension by causing vasodilation of the pulmonary blood vessels.
Buyer Products:
|
|
|
|
Thromboembolism |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.
Buyer Products:
|
|
|
|
Dermatology |
|
|
|
Lesion/Scaling Disorders |
|
|
|
Dermatitis |
|
|
|
Atopic (Eczema) |
|
|
|
Immunomodulators
Therapeutics that treat atopic dermatitis by inhibiting T-lymphocyte activation.
Buyer Products:
|
|
|
|
Seborrheic (Dandruff) |
|
|
|
Coal Tar
A coal byproducts used in the treatment of various skin disorders.
Buyer Products:
|
|
|
|
Diaper Rash |
|
|
|
Zinc Oxide
Therapeutics that treat diaper rash by forming a protective barrier against the skin.
Buyer Products:
|
|
|
|
Psoriasis |
|
|
|
Peroxisome Proliferator-Activated Receptor Agonists (PPAR Agonists)
Therapeutics that treat psoriasis by stimulating immune response and regulating inflammation and skin cell proliferation.
Buyer Products:
|
|
|
|
Digestive System |
|
|
|
Gastrointestinal Tract Disorders |
|
|
|
Gastroduodenal Disorders |
|
|
|
Peptic Ulcers |
|
|
|
Duodenal |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat peptic ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Gastric |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat peptic ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Zollinger-Ellison Syndrome |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Gastroesophageal Disorders |
|
|
|
Abdominal Gas |
|
|
|
Gas Bubble Surface Tension Reducing Agents
Therapeutics that treat abdominal gas by reducing the surface tension of gas bubbles in the bowels.
Buyer Products:
|
|
|
|
Acid Indigestion/Heartburn |
|
|
|
Acid Neutralizing Agents
Therapeutics that treat heartburn by neutralizing stomach acid.
Buyer Products:
|
|
|
|
H2 Receptor Antagonists
Therapeutics that treat indigestion by blocking the action of histamine at the H2 receptors.
Buyer Products:
|
|
|
|
Erosive Esophagitis |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat Erosive Esophagitis by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Gastroesophageal Reflux Disease (GERD) |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat Gastroesophageal Reflux Disease by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Nausea/Vomiting |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat or prevent nausea and vomiting by blocking the action of dopamine.
Buyer Products:
|
|
|
|
Neurokinin-1 (NK-1) Receptor Antagonists
Therapeutics that prevent or treat nausea and vomiting by inhibiting the neurotransmitter NK-1 (Substance P) from binding to its receptors.
Buyer Products:
|
|
|
|
Serotonin Receptor Antagonists
Therapeutics that treat nausea and vomiting by blocking the serotonin receptors.
Buyer Products:
|
|
|
|
Intestinal Disorders |
|
|
|
Constipation |
|
|
|
Chronic |
|
|
|
Bulk-Forming Agents
Therapeutics that treat constipation by stimulating the formation of bodies of feces that are able to be passed through the bowels.
Buyer Products:
|
|
|
|
Opioid Receptor Antagonists
Therapeutics that treat constipation by blocking the mu opioid receptors in the intestines.
Buyer Products:
|
|
|
|
Irregular Bowel Movements |
|
|
|
Bulk-Forming Agents
Therapeutics that treat constipation by stimulating the formation of bodies of feces that are able to be passed through the bowels.
Buyer Products:
|
|
|
|
Opioid Receptor Antagonists
Therapeutics that treat constipation by blocking the mu opioid receptors in the intestines.
Buyer Products:
|
|
|
|
Liver Disorders |
|
|
|
Hepatitis |
|
|
|
Hepatitis B |
|
|
|
Chronic |
|
|
|
Reverse Transcriptase Inhibitors (Nucleoside Analogs)
Therapeutics that treat hepatitis by inhibiting the action of reverse transcriptase, an enzyme necessary for DNA synthesis using an RNA template.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Endocrinology/Metabolism |
|
|
|
Diabetes |
|
|
|
Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes |
|
|
|
Biguanides/Peroxisome Proliferator-Activated Receptor Agonists (PPAR Agonists)
Therapeutics that control high blood sugar by stimulating the release of insulin as well as sensitizing organs to insulin.
Buyer Products:
|
|
|
|
Insulin Stimulating Agents (Sulfonylureas)/PPAR Agonists
Therapeutics that treat non-insulin dependent diabetes by stimulating the secretion of insulin and sensitizing organs to insulin.
Buyer Products:
|
|
|
|
Peroxisome Proliferator-Activated Receptor Agonists (PPAR Agonists)
Products that sensitize organs to insulin.
Buyer Products:
|
|
|
|
Intermediary Metabolism Disorders |
|
|
|
Hypercholesterolemia |
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Hyperlipidemia |
|
|
|
Omega-3 Acid Ethyl Esters
Omega-3 acid ethyl ester therapeutics that lower excessive triglyceride levels.
Buyer Products:
|
|
|
|
Porphyrias |
|
|
|
Acute Intermittent |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat porphyrias by blocking the receptor that binds the neurotransmitter, dopamine.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Hematology |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Serum Factor Disorders |
|
|
|
Hypercholesterolemia |
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Hyperlipidemia |
|
|
|
Omega-3 Acid Ethyl Esters
Omega-3 acid ethyl ester therapeutics that lower excessive triglyceride levels.
Buyer Products:
|
|
|
|
Thrombocyte (Platelet) Disorders |
|
|
|
Thrombocytopenia |
|
|
|
Thrombopoietin Agonists
Therapeutics that treat thrombocytopenia by stimulating thrombopoietin, which promotes the production of platelets.
Buyer Products:
|
|
|
|
Immunology |
|
|
|
Autoimmune Disorders |
|
|
|
Arthritis |
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Analgesics |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Buyer Products:
|
|
|
|
Idiopathic Thrombocytopenia Purpura (ITP) |
|
|
|
Thrombopoietin Agonists
Therapeutics that treat thrombocytopenia by stimulating thrombopoietin, which promotes the production of platelets.
Buyer Products:
|
|
|
|
Lupus Erythematosus |
|
|
|
Systemic (SLE) |
|
|
|
Monoclonal Antibodies
Therapeutics that treat systemic lupus by binding to certain receptors on antigens associated with the disease, thus modulating the immune reaction.
Buyer Products:
|
|
|
|
Psoriasis |
|
|
|
Peroxisome Proliferator-Activated Receptor Agonists (PPAR Agonists)
Therapeutics that treat psoriasis by stimulating immune response and regulating inflammation and skin cell proliferation.
Buyer Products:
|
|
|
|
Immune Deficiency Disorders |
|
|
|
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) |
|
|
|
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.
Buyer Products:
|
|
|
|
Protease Inhibitors
Therapeutics that help manage HIV by binding to and blocking the action of HIV protease, an enzyme necessary for viral replication.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Infectious Diseases |
|
|
|
Bacterial |
|
|
|
Antibacterial Agents |
|
|
|
Broad Spectrum |
|
|
|
Antibiotics |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Penicillin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis during active multiplication.
Buyer Products:
|
|
|
|
Penicillin Derivatives/Beta-Lactamase Inhibitors
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis during active multiplication and increasing susceptibility to penicillin derived compounds.
Buyer Products:
|
|
|
|
Pleuromutilins
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis through binding onto ribosome.
Buyer Products:
|
|
|
|
Pseudominic Acids
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis and RNA synthesis.
Buyer Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Musculoskeletal System |
|
|
|
Bone/Joint Infections |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat bacterial infections manifested in the bones or joints by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Neurology |
|
|
|
Meningitis |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat inflammation of the lining of the brain and spinal cord by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Otolaryngology (Ear/Nose/Throat) |
|
|
|
Otitis Media |
|
|
|
Penicillin Derivatives/Beta-Lactamase Inhibitors
Therapeutics that treat infection and inflammation of the middle ear space and ear drum by inhibiting bacterial cell wall synthesis during active multiplication and increasing susceptibility to penicillin derived compounds.
Buyer Products:
|
|
|
|
Respiratory System |
|
|
|
Pharyngitis |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat inflammation of the cone shaped cavity at the back of the mouth caused by bacterial infection by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Respiratory Tract Infections |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat infections of the air passage caused by a wide variety of bacteria.
Buyer Products:
|
|
|
|
Tonsilitis |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat inflammation of the lymphoid tissue on either side of the throat caused by bacterial infection by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Vaccines |
|
|
|
Bacterial |
|
|
|
Combination |
|
|
|
Diphtheria/Tetanus/Acellular Pertussis (DTaP)
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause diphtheria, tetanus, and acellular pertussis.
Buyer Products:
|
|
|
|
Single Target |
|
|
|
Haemophilus Influenzae Type B (Hib)
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause Haemophilus influenzae type B.
Buyer Products:
|
|
|
|
Meningitis
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause meningitis.
Buyer Products:
|
|
|
|
Streptococcus pneumoniae
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause pneumococcal bacteria.
Buyer Products:
|
|
|
|
Typhoid Fever
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause typhoid fever.
Buyer Products:
|
|
|
|
Bacterial/Viral
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to a bacterial or viral pathogen.
Buyer Products:
|
|
|
|
Helminthic |
|
|
|
Hydatid Disease |
|
|
|
Antimicrotubule Agents
Therapeutics that treat parasitic infections characterized by formation of cysts in a several organs.
Buyer Products:
|
|
|
|
Neurocysticercosis |
|
|
|
Antimicrotubule Agents
Therapeutics that treat parasitic infections caused by a tapeworm in the brain.
Buyer Products:
|
|
|
|
Mycological (Fungal) |
|
|
|
Antifungal Agents |
|
|
|
Narrow Spectrum |
|
|
|
Respiratory System |
|
|
|
Pneumocystis Carinii Pneumonia (PCP) |
|
|
|
Protozoan Metabolism Inhibitors
Therapeutics that treat infections of the lungs of immunocompromised patients caused by Pneumocystis carinii by preventing metabolism and growth in organism.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Protozoal |
|
|
|
Antiprotozoal Agents |
|
|
|
Narrow Spectrum |
|
|
|
Malaria |
|
|
|
Dihydrofolate Reductase Inhibitors
Therapeutics that treat parasitic infections caused by Plasmodia in red blood cells by blocking the action of the dihydrofolate enzyme.
Buyer Products:
|
|
|
|
Toxoplasmosis (Toxo) |
|
|
|
Dihydrofolate Reductase Inhibitors
Therapeutics that treat infections caused by Toxoplasma gondii and characterized by lesions in the heart, brain, and eye by preventing folic acid synthesis.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in very early stages of research where no human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Viral |
|
|
|
DNA Viruses |
|
|
|
Hepadnavirus |
|
|
|
Hepatitis B |
|
|
|
Chronic |
|
|
|
Reverse Transcriptase Inhibitors (Nucleoside Analogs)
Therapeutics that treat viral infections characterized by inflammation of the liver for more than six months by blocking enzyme essential for viral DNA synthesis.
Buyer Products:
|
|
|
|
Herpesvirus |
|
|
|
Herpes Labialis (Cold Sores) |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
|
Viral Fusion Inhibitors
Therapeutics that treat cold sores by inhibiting fusion of viral material into human cell plasma membranes.
Buyer Products:
|
|
|
|
Herpes Simplex Type 1 |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections characterized by recurrent cold sores and fever blisters by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
|
Herpes Simplex Type 2 |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections characterized by recurring outbreaks of painful genital lesions by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
|
Varicella Zoster |
|
|
|
Herpes Zoster (Shingles) |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections that cause shingles in adults by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
|
Varicella (Chickenpox) |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections that cause chicken pox in children by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
|
RNA Viruses |
|
|
|
Orthomyxovirus |
|
|
|
Influenza A |
|
|
|
Neuraminidase Inhibitors
Therapeutics that treat viral infections of the respiratory tract caused by Influenza A virus by preventing the release of new viruses from infected cells.
Buyer Products:
|
|
|
|
Influenza B |
|
|
|
Neuraminidase Inhibitors
Therapeutics that treat viral infections of the respiratory tract caused by Influenza B virus by preventing the release of new viruses from infected cells.
Buyer Products:
|
|
|
|
Retrovirus |
|
|
|
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) |
|
|
|
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.
Buyer Products:
|
|
|
|
Protease Inhibitors
Therapeutics that help manage HIV by binding to and blocking the action of HIV protease, an enzyme necessary for viral replication.
Buyer Products:
|
|
|
|
Vaccines |
|
|
|
Bacterial/Viral
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to a bacterial and viral pathogens.
Buyer Products:
|
|
|
|
Viral |
|
|
|
Combination |
|
|
|
Hepatitis A/Hepatitis B
Therapeutics that prevent or treat viral infections of the liver by producing or artificially increasing immunity to Hepatitis A and Hepatitis B viruses.
Buyer Products:
|
|
|
|
Measles/Mumps/Rubella
Therapeutics that prevent or treat viral infections by producing or artificially increasing immunity to measles, mumps, and rubella.
Buyer Products:
|
|
|
|
Single Target |
|
|
|
Hepatitis A
Therapeutics that prevent or treat viral infections of the liver by producing or artificially increasing immunity to the Hepatitis A virus.
Buyer Products:
|
|
|
|
Hepatitis B
Therapeutics that prevent or treat viral infections of the liver by producing or artificially increasing immunity to the Hepatitis B virus.
Buyer Products:
|
|
|
|
Herpes Simplex
Therapeutics that prevent or treat viral infections characterized by vesicular eruption by producing or artificially increasing immunity to the Herpes Simplex virus.
Buyer Products:
|
|
|
|
Influenza (Flu)
Therapeutics that prevent or treat viral infections of the respiratory tract by producing or artificially increasing immunity to the Influenza virus.
Buyer Products:
|
|
|
|
Japanese Encephalitis
Therapeutics that prevent or treat viral infections characterized by inflammation of the brain by producing or artificially increasing immunity to the Japanese B Encephalitis virus.
Target Products:
|
|
|
|
Papillomavirus
Therapeutics that prevent or treat viral infections characterized by the proliferation of epithelial cells, leading to the formation of warts and possibly other related diseases such as cervical pre-cancers and cervical cancer.
Buyer Products:
|
|
|
|
Rabies
Therapeutics that prevent or treat viral infections that infect brain cells by producing or artificially increasing immunity to the rabies virus.
Buyer Products:
|
|
|
|
Rotavirus
Therapeutics that prevent or treat viral infections that cause severe dehydrating diarrhea in children by producing or artificially increasing immunity to the rotavirus.
Buyer Products:
|
|
|
|
Varicella-Zoster Virus (Chicken Pox)
Therapeutics that prevent or treat viral infections that cause a blistery red rash by producing or artificially increasing immunity to the Varicella Zoster virus.
Buyer Products:
|
|
|
|
Variola (Smallpox)
Therapeutics that prevent or treat viral infections that cause a diffuse and extensive distribution of lesions by producing or artificially increasing immunity to the Variola virus.
Target Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Skeletal Disorders |
|
|
|
Bone Disorders |
|
|
|
Osteoporosis |
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts.
Buyer Products:
|
|
|
|
Joint Disorders |
|
|
|
Osteoarthritis (OA) |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
|
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Analgesics |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Buyer Products:
|
|
|
|
Neurology |
|
|
|
Neurological Disorders |
|
|
|
Alzheimer`s Disease |
|
|
|
Peroxisome Proliferator-Activated Receptor Agonists (PPAR Agonists)
Therapeutics that treat Alzheimer's Disease by stimulating immune response and regulating inflammation.
Buyer Products:
|
|
|
|
Epilepsy |
|
|
|
Partial Seizures |
|
|
|
Complex |
|
|
|
Adjunctive Therapy |
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat complex partial seizures by blocking the sodium channels which in turn block the conductance of neural impulses through the brain.
Buyer Products:
|
|
|
|
Monotherapy |
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat complex partial seizures by blocking the sodium channels which in turn block the conductance of neural impulses through the brain.
Buyer Products:
|
|
|
|
Simple |
|
|
|
Monotherapy |
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat simple partial seizures by blocking the sodium channels which in turn block the conductance of neural impulses.
Buyer Products:
|
|
|
|
Headaches |
|
|
|
Chronic |
|
|
|
Analgesics/Antipyretics/Antihistamines
Therapeutics that treat headaches through management of pain, fever and the proliferation of molecules that causes inflammation.
Buyer Products:
|
|
|
|
Cluster |
|
|
|
Selective Serotonin Receptor Agonists (Triptans)
Therapeutics that treat Cluster Headaches by blocking the receptor that binds with the neurotransmitter, serotonin.
Buyer Products:
|
|
|
|
Vascular (Migraine) |
|
|
|
Acute Treatments |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) Combinations |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID)/Selective Serotonin Receptor Agonists
Therapeutics that treat vascular headaches by inhibiting the action of cyclooxygenase, which is an inflammatory substance, as well as stimulating the serotonin receptor.
Buyer Products:
|
|
|
|
Selective Serotonin Receptor Agonists (Triptans)
Therapeutics that treat vascular/migraine headaches by stimulating the receptor that binds with the neurotransmitter, serotonin.
Buyer Products:
|
|
|
|
Neuromuscular Disorders |
|
|
|
Parkinson`s Disease (PD) |
|
|
|
Monotherapy |
|
|
|
Dopamine Receptor Agonists
Therapeutics that treat the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by stimulating dopamine receptors on the neurons.
Buyer Products:
|
|
|
|
Restless Leg Syndrome |
|
|
|
Dopamine Receptor Agonists
Therapeutics that treat Restless Leg Syndrome by stimulating dopamine activity.
Buyer Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors |
|
|
|
Singultus (Hiccups) |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat hiccups by blocking the action of the dopamine receptors in the brain and also peripherally acting on the vagus nerve, which may be responsible for the involuntary contractions.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Psychiatric Disorders |
|
|
|
Anxiety |
|
|
|
Generalized Anxiety Disorder (GAD) |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat anxiety by blocking dopamine receptors.
Buyer Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat anxiety by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Obsessive Compulsive Disorder (OCD) |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat Anxiety by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Panic Disorder |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat panic disorder by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Post-Traumatic Stress Disorder (PTSD) |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat post traumatic stress disorder by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Social Anxiety Disorder (SAD) |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat Social Anxiety Disorder by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Childhood/Adolescent Disorders |
|
|
|
Attention Deficit Disorder (ADD)/Attention Deficit Hyperactivity Disorder (ADHD) |
|
|
|
Sympathomimetic Agents
Therapeutic members of the amphetamine group of sympathomimetic amines that treat the disorder involving hyperactivity in children due to an abnormally short attention span.
Buyer Products:
|
|
|
|
Mood Disorders |
|
|
|
Bipolar Disorders (Manic Depressive Disorders) |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat bipolar disorders by blocking the dopamine receptors.
Buyer Products:
|
|
|
|
Lithium-Based Agents
Therapeutics that treat bipolar disorders by decreasing the concentrations of neurotransmitters.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat bipolar disorders by blocking the sodium channels which in turn prevents the conductance of nerve impulses.
Buyer Products:
|
|
|
|
Depression |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat depression by blocking the dopamine receptors.
Buyer Products:
|
|
|
|
Monoamine Oxidase (MAO) Inhibitors
Therapeutics that treat depression by inhibiting the activity of monoamine oxidase, which degrades neurotransmitters.
Buyer Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat depression by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Serotonin Receptor Agonists
Therapeutics that treat depression by stimulating the serotonin receptors.
Buyer Products:
|
|
|
|
Serotonin/Norepinephrine Reuptake Inhibitors
Therapeutics that treat depression by inhibiting the neuronal uptake of serotonin and norepinephrine.
Buyer Products:
|
|
|
|
Premenstrual Dysphoric Disorders |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat premenstrual dysphoric disorders by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Schizophrenia |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat schizophrenia by blocking the dopamine receptors.
Buyer Products:
|
|
|
|
Sleep Disorders |
|
|
|
Insomnia |
|
|
|
Antihistamines
Therapeutics that treat insomnia by preventing the functions of histamine on tissues.
Buyer Products:
|
|
|
|
Antihistamines/Analgesics/Antipyretics
Therapeutics that treat insomnia by preventing the functions of histamine on tissues as well as treating pain and suppressing fever.
Buyer Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat insomnia by enhancing the inhibitory action of gamma-aminobutyric acid.
Buyer Products:
|
|
|
|
Narcolepsy |
|
|
|
Sympathomimetic Agents
Therapeutic members of the amphetamine group of sympathomimetic amines that treat the disorder involving hronic and sudden daytime sleepiness.
Buyer Products:
|
|
|
|
Obstetrics/Gynecology |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of female reproductive disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Oncology |
|
|
|
Breast Cancer |
|
|
|
Metastatic |
|
|
|
Tyrosine Kinase Inhibitors
Therapeutics that treat breast cancer by inhibiting the action of tyrosine kinase, enzymes that play a vital role in cell division.
Buyer Products:
|
|
|
|
Dermatology |
|
|
|
Malignant Melanoma |
|
|
|
Reactive Oxygen Species (ROS) Inducers
Therapeutics that treat skin cancer by inducing oxidative stress inside tumor cells and triggering programmed cell death.
Buyer Products:
|
|
|
|
Hematology |
|
|
|
Leukemia (White Blood Cell Cancer) |
|
|
|
Lymphoid |
|
|
|
Acute |
|
|
|
Lymphoblastic |
|
|
|
Antimetabolite Agents |
|
|
|
Purine Analogs
Therapeutics that treat and manage rapidly progressing cancers of immature lymphocytic cells by interfering with nucleic acid biosynthesis.
Buyer Products:
|
|
|
|
Myeloid |
|
|
|
Acute |
|
|
|
Myeloblastic |
|
|
|
Antimetabolite Agents |
|
|
|
Purine Analogs
Therapeutics that treat and manage rapidly progressing cancers affecting immature cells of the bone marrow by interfering with nucleic acid biosynthesis.
Buyer Products:
|
|
|
|
Myelogenous (AML) |
|
|
|
Antimetabolite Agents |
|
|
|
Purine Analogs
Therapeutics that treat and manage rapidly progressing cancers of the myelogenous cellsby interfering with nucleic acid biosynthesis.
Buyer Products:
|
|
|
|
Palliative Agents |
|
|
|
Alkylating Agents |
|
|
|
Alkylsulfonates
Therapeutics that treat and manage cancers of myeliod cells by cross-linking and breaking DNA strands which ultimately leads to cell death.
Buyer Products:
|
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage cancers of myeliod cells by interacting with DNA and inhibiting cell division but are not curative.
Buyer Products:
|
|
|
|
Lymphoma (Lymphatic Cancer) |
|
|
|
Hodgkin`s Disease |
|
|
|
Palliative Agents |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage lymphoma characterized by the presence of Reed-Sternberg cells by interacting with DNA and inhibiting cell division but that are not curative.
Buyer Products:
|
|
|
|
Non-Hodgkin`s Lymphoma (NHL) |
|
|
|
Antimetabolite Agents |
|
|
|
Purine Analogs
Therapeutics that treat and manage lymphomas of B-cells and T-cells by interfering with nucleic acid biosynthesis.
Buyer Products:
|
|
|
|
Palliative Agents |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage lymphomas of B-cells and T-cells by interacting with DNA and inhibiting cell division but are not curative.
Buyer Products:
|
|
|
|
Radioactive Agents/Monoclonal Antibodies
Therapeutics that utilize a monoclonal antibody to target a local dose of radiation to lymphoma cells in order to induce their death.
Buyer Products:
|
|
|
|
Multiple Myeloma (Plasma Cell Cancer) |
|
|
|
Palliative Agents |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage cancers of mature antibody producing white blood cells by interacting with DNA and inhibiting cell division but are not curative.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.
Buyer Products:
|
|
|
|
Respiratory System/Thoracic |
|
|
|
Lung Cancer |
|
|
|
Non Small Cell Lung Cancer (NSCLC) |
|
|
|
Antimicrotubule Agents
Therapeutics that treat and manage cancers of the lung including squamous cell carcinoma, adenocarcinoma and large cell carcinoma by blocking the normal function of microtubules, thus inhibiting cell division.
Buyer Products:
|
|
|
|
Vaccines
Therapeutics that are meant to promote an immune response against a patient's non-small cell lung cancer (NSCLC).
Buyer Products:
|
|
|
|
Small Cell Lung Cancer (SCLC) |
|
|
|
Topoisomerase I Inhibitors
Therapeutics that treat and manage cancers of the small cells in the lung by inhibiting a specific enzyme, topoisomerase I, which is needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Cervical Cancer |
|
|
|
Localized |
|
|
|
Papillomavirus Vaccines
Therapeutics that are meant to promote an immune response against the Papillomavirus that are involved in the pathogenesis of cervical cancer.
Buyer Products:
|
|
|
|
Topoisomerase I Inhibitors
Therapeutics that treat and manage cancers of the cervix by inhibiting a specific enzyme, topoisomerase I, which is needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Kidney Cancer (Renal Cell Carcinoma) |
|
|
|
Metastatic |
|
|
|
Tyrosine Kinase Inhibitors
Therapeutics that treat kidney cancer by inhibiting the action of tyrosine kinase, enzymes that play a vital role in cell division.
Buyer Products:
|
|
|
|
VEGFR/EGFR-TK Inhibitors
Therapeutics that treat lung cancer by binding to the epidermal growth factor receptors (EGFR) and the vascular endothelial growth factor receptors (VEGFR), thereby disrupting cell growth regulation and inhibiting the formation of blood vessels around tumor cells.
Buyer Products:
|
|
|
|
Ovarian Cancer |
|
|
|
Adenocarcinoma |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage cancer of cells lining the ovary by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Metastatic |
|
|
|
Topoisomerase I Inhibitors
Therapeutics that treat and manage ovarian cancers that have spread beyond their original tumor site by inhibiting a specific enzyme, topoisomerase I, needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Prostate Cancer |
|
|
|
Localized |
|
|
|
5-Alpha Reductase Inhibitors
Therapeutics that treat prostate cancer by inhibiting the formation of Dihydrotestosterone from testosterone.
Buyer Products:
|
|
|
|
Ophthalmology |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of eye disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Pain Management |
|
|
|
Non-Narcotics |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
|
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) Combinations |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID)/Analgesics/Antipyretics
Therapeutics that treat pain and fever by inhibiting the action of prostaglandins.
Buyer Products:
|
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID)/Analgesics/Antipyretics/Caffeine
Therapeutics that treat pain and fever by inhibiting the action of prostaglandins.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of pain in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of pain in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Respiratory System |
|
|
|
Lower Respiratory Tract Disorders (Lung Disorders) |
|
|
|
Asthma |
|
|
|
Acute Treatments |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Prophylactic Treatments |
|
|
|
Beta Adrenergic Receptor Agonists/Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat asthma by reducing inflammation in the lungs with steroids and that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat asthma by reducing inflammation in the lung passages with steroids.
Buyer Products:
|
|
|
|
Bronchitis |
|
|
|
Acute Treatments |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Bronchospasm |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Chronic Obstructive Pulmonary Disease (COPD) |
|
|
|
Acute Treatments |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Prophylactic Treatments |
|
|
|
Beta Adrenergic Receptor Agonists/Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that are used to prevent COPD attacks by preventing inflammation and stimulating beta adrenergic receptors.
Buyer Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that are used to prevent COPD attacks by reducing inflammation in the lung passages with steroids.
Buyer Products:
|
|
|
|
Respiratory Distress Syndrome (RDS) |
|
|
|
Surfactants
Therapeutics that treat RDS by modifying alveolar surface tension and thereby stabilizing the alveoli.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Upper Respiratory Tract Disorders |
|
|
|
Coughs/Colds |
|
|
|
Anticholinergic Agents/Opioids
Therapeutics that treat coughs and colds by relieving pain and fever as well as suppressing cough.
Buyer Products:
|
|
|
|
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
|
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and reduces the amount of mucous build up.
Buyer Products:
|
|
|
|
Antihistamines/Decongestants/Analgesics/Antipyretics
Therapeutics that treat coughs and colds by suppressing inflammation, reducing mucous build up, relieving pain, and reducing fever.
Buyer Products:
|
|
|
|
Antihistamines/Decongestants/Antitussives/Analgesics/Antipyretics
Therapeutics that treat coughs and colds by suppressing inflammation, reducing mucous build up, relieving or preventing coughs, relieving pain, and reducing fever.
Buyer Products:
|
|
|
|
Decongestants/Analgesics/Antipyretics
Therapeutics that treat coughs and colds by reducing mucous build up, relieving pain, and reducing fever.
Buyer Products:
|
|
|
|
Decongestants/Antitussives/Analgesics/Antipyretics
Therapeutics that treat coughs and colds by reducing mucous build up, suppressing coughs and relieving pain and fever.
Buyer Products:
|
|
|
|
Decongestants/Antitussives/Expectorants/Analgesics/Antipyretics
Therapeutics that treat coughs and colds by reducing mucous build up, suppressing the cough, helping in the ejection of mucous and helping relieve fever and pain.
Buyer Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress the inflammation in the upper respiratory tract with steroidal compounds.
Buyer Products:
|
|
|
|
Nasal Dryness |
|
|
|
Moisturizing Agents
Therapeutics that treat nasal dryness by providing moisture to the nasal passages.
Buyer Products:
|
|
|
|
Surgery |
|
|
|
Digestive System |
|
|
|
Post-Operative Ileus/Constipation |
|
|
|
Opioid Receptor Antagonists
Therapeutics that treat constipation by blocking the mu opioid receptors in the intestines.
Buyer Products:
|
|
|
|
General |
|
|
|
Complications |
|
|
|
Nausea/Vomiting |
|
|
|
Serotonin Receptor Antagonists
Therapeutics that prevent or treat post surgical nausea and vomiting by blocking the receptors that bind serotonin, a neurotransmitter.
Buyer Products:
|
|
|
|
Restlessness/Apprehension |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat the nervousness which precedes surgery by blocking the receptor that binds the neurotransmitter, dopamine.
Buyer Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Deep Vein Thrombosis (DVT) |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Thrombin Inhibitors
Therapeutics that treat vascular obstructions due to platelets and cell matter by blocking an enzyme involved in the clotting process.
Buyer Products:
|
|
|
|
Toxicology |
|
|
|
Chemical Poisoning |
|
|
|
Digoxin |
|
|
|
Digoxin Binding Agents
Therapeutics that treat toxicity due to ingestion of excessive digoxin by competitively binding to digoxin, making them unavailable for binding at their site of action on cells in the body.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of toxicity in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Substance Abuse |
|
|
|
Withdrawal |
|
|
|
Nicotine (Smoking Cessation) |
|
|
|
Nicotinic Receptor Agonists
Therapeutics that treat nicotine withdrawal by activating nicotine receptors thus reducing cravings for nicotine.
Buyer Products:
|
|
|
|
Serotonin/Norepinephrine Reuptake Inhibitors
Therapeutics that increase the concentration of several neurotransmitters in the brain by inhibiting their uptake.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Male Genital Disorders |
|
|
|
Penile |
|
|
|
Erectile Dysfunction (Impotence) |
|
|
|
Phosphodiesterase Type 5 Inhibitors (PDE-5 Inhibitors)
Therapeutics that inhibit the break down of phosphodiesters thereby increasing levels of Nitric Oxide which help in dilating the blood vessels in the penis.
Buyer Products:
|
|
|
|
Prostate |
|
|
|
Benign Prostate Hyperplasia (BPH) |
|
|
|
5-Alpha Reductase Inhibitors
Therapeutics that inhibit the transformation of testosterone into dihydrotestosterone (DHT), a substance that causes enlargement of the prostate.
Buyer Products:
|
|
|
|
5-Alpha Reductase Inhibitors/Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)
Therapeutics that inhibit the transformation of testosterone into dihydrotestosterone (DHT)--a substance that causes enlargement of the prostate, and also causes the smooth muscle in the prostate to relax and decreasing the constriction on the urinary tract.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Urological Disorders |
|
|
|
Bladder |
|
|
|
Urinary Frequency/Urge Incontinence |
|
|
|
Muscarinic Receptor Antagonists
Therapeutics that treat the inability to control urinary excretory functions by blocking the action of choline and other cholinergic agents by binding to the muscarinic receptor.
Buyer Products:
|
|
|
|
Weight Management |
|
|
|
Obesity |
|
|
|
Lipase Inhibitors
Therapeutics that reduce the absorption of fat by inhibiting production of lipase, which is an enzyme that helps breaking down fat in the food.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of weight disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Medical Devices |
|
|
|
Clinical Diagnostics |
|
|
|
Immunoassays |
|
|
|
Reagents |
|
|
|
Test Kits |
|
|
|
Allergy |
|
|
|
Specific Allergen
Allergy test kits specific to a single allergen.
Buyer Products:
|
|
|
|
Microbiology |
|
|
|
Culture and Sensitivity |
|
|
|
Identification/Manual |
|
|
|
Reagents |
|
|
|
Identification Confirmation |
|
|
|
Bacterial |
|
|
|
Enterococcus/VRE
Confirmatory test for identification of suspected Enterococcus from culture isolates.
Buyer Products:
|
|
|
|
Staphylococcus/MRSA
Test kits used to identify Staphylococcus bacteria in a culture source.
Buyer Products:
|
|
|
|
Drug Delivery |
|
|
|
Pulmonary Delivery |
|
|
|
Aerosol Therapy |
|
|
|
Metered Dose |
|
|
|
Dry Powder |
|
|
|
Inhalers (DPI)
Mouthpiece-type of medical devices from which the patients inhale the medication mixture
Buyer Products:
|
|
|
|
Liquid |
|
|
|
Breath Actuated (BAI)
Inhalation devices which are activated by the patients' inspiration
Buyer Products:
|
|
|
|
Manual
Inhalation devices which are activated by the patient's manual control
Buyer Products:
|
|
|
|
Respiratory |
|
|
|
Treatment |
|
|
|
Nasal Expanders
Device designed to expand the nasal passages.
Buyer Products:
|
|
|
|
Nutritional Health |
|
|
|
Dietary/Naturopathic Supplements |
|
|
|
General Health
Products consisting of dietary/naturopathic supplements that are intended to support general health.
Buyer Products:
|
|
|
|
Women`s Health
Products consisting of dietary/naturopathic supplements that are intended to support women's health.
Buyer Products:
|
|
|
|
Outsourced Services |
|
|
|
Development/Manufacturing Services |
|
|
|
Contract Manufacturing Organizations (CMO) |
|
|
|
Pharmaceuticals |
|
|
|
Biologics
Active Ingredient Contract Manufacturing Organizations (CMO) that manufacture antibodies, proteins, and genetic materials.
Buyer Products:
|
|
|
|
Scientific Products |
|
|
|
Consumables |
|
|
|
Bioanalytical Chemistry |
|
|
|
Cell Biology |
|
|
|
Cell Culture |
|
|
|
Cell Lines
Cell biology consumables that is a permanently established cell culture which proliferates indefinitely given appropriate fresh medium and space.
Buyer Products:
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Relationship Details
Key Competitors
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
Novartis AG (ADR)
|
|
n/a | 118,023.291 | 9.88 | 14.54 | 3.03 | 2.93 | 4.22 | |
|
Sanofi-Aventis SA (ADR)
|
|
n/a | 105,870.385 | 12.98 | 9.45 | 2.34 | 2.48 | n/a | |
|
Merck & Co., Inc.
|
|
n/a | 87,371.039 | 26.67 | 11.62 | 3.61 | 3.38 | 5.45 | |
|
Crucell N.V. (ADR)
|
|
n/a | 1,092.667 | 0.00 | -31.39 | 3.46 | 2.64 | 2.47 | |
|
Emergent BioSolutions Inc.
|
|
n/a | 274.297 | 11.96 | 11.83 | 1.50 | 1.51 | 1.60 | |
|
AVANT Immunotherapeutics, Inc.
|
|
n/a | 157.928 | 0.00 | -5.31 | 30.95 | 15.37 | n/a | |
|
DOR BioPharma, Inc.
|
|
n/a | 17.059 | 0.00 | n/a | 10.61 | n/a | 9.94 | |
| Buyer | |||||||||
|
The Procter & Gamble Company
|
|
n/a | 217,271.353 | 19.75 | 20.19 | 2.72 | 2.62 | n/a | |
|
Johnson & Johnson
|
|
n/a | 186,001.375 | 17.59 | 14.73 | 3.04 | 2.90 | 12.78 | |
|
Roche Holding Ltd. (ADR)
|
|
n/a | 163,455.599 | 16.51 | 19.02 | 3.49 | 3.93 | 5.01 | |
|
Pfizer Inc.
|
|
n/a | 144,404.316 | 17.74 | 9.00 | 2.98 | 2.99 | 6.24 | |
|
Novartis AG (ADR)
|
|
n/a | 118,023.291 | 9.88 | 14.54 | 3.03 | 2.93 | 4.22 | |
|
Sanofi-Aventis SA (ADR)
|
|
n/a | 105,870.385 | 12.98 | 9.45 | 2.34 | 2.48 | n/a | |
|
Unilever plc (ADR)
|
|
n/a | 100,156.776 | 16.35 | 17.96 | 1.58 | 1.76 | n/a | |
|
Unilever N.V. (ADR)
|
|
n/a | 99,189.219 | 16.19 | 16.06 | 1.57 | 1.68 | n/a | |
| Target | |||||||||
|
GlaxoSmithKline plc (ADR)
|
|
n/a | 122,737.730 | 11.80 | 11.47 | 2.71 | 2.67 | 16.29 | |
|
Novartis AG (ADR)
|
|
n/a | 118,023.291 | 9.88 | 14.54 | 3.03 | 2.93 | 4.22 | |
|
Sanofi-Aventis SA (ADR)
|
|
n/a | 105,870.385 | 12.98 | 9.45 | 2.34 | 2.48 | n/a | |
|
Merck & Co., Inc.
|
|
n/a | 87,371.039 | 26.67 | 11.62 | 3.61 | 3.38 | 5.45 | |
|
Crucell N.V. (ADR)
|
|
n/a | 1,092.667 | 0.00 | -31.39 | 3.46 | 2.64 | 2.47 | |
|
Emergent BioSolutions Inc.
|
|
n/a | 274.297 | 11.96 | 11.83 | 1.50 | 1.51 | 1.60 | |
|
Optimer Pharmaceuticals, Inc.
|
|
n/a | 182.597 | 0.00 | -5.74 | 237.86 | 180.66 | 3.45 | |
|
AVANT Immunotherapeutics, Inc.
|
|
n/a | 157.928 | 0.00 | -5.31 | 30.95 | 15.37 | n/a | |
|
SIGA Technologies, Inc.
|
|
n/a | 97.451 | 0.00 | -10.00 | 14.55 | 9.34 | 22.51 | |
|
DOR BioPharma, Inc.
|
|
n/a | 17.059 | 0.00 | n/a | 10.61 | n/a | 9.94 | |
- Defined by the Company
- Defined by Others
Dependent Suppliers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
|
Antigenics, Inc.
|
|
n/a | 141.469 | 0.00 | -3.17 | 25.47 | n/a | n/a | |
| Buyer | |||||||||
|
Cytokinetics, Inc.
|
|
97.00% | 169.596 | 0.00 | -2.51 | 12.45 | 14.15 | 1.70 | |
|
Encysive Pharmaceuticals, Inc.
|
|
91.50% | 190.263 | 0.00 | n/a | 5.30 | 3.29 | n/a | |
|
Flamel Technologies S.A. (ADR)
|
|
66.50% | 230.318 | 0.00 | -19.08 | 6.28 | 3.55 | n/a | |
|
Human Genome Sciences
|
|
48.00% | 865.347 | 0.00 | -5.28 | 20.67 | 4.97 | n/a | |
|
Theravance, Inc.
|
|
39.80% | 728.345 | 0.00 | -6.45 | 33.11 | 19.54 | n/a | |
|
Response Genetics, Inc.
|
|
39.50% | 38.909 | 0.00 | n/a | 4.99 | n/a | 2.58 | |
|
PDI, Inc.
|
|
28.20% | 123.199 | 0.00 | -14.79 | 1.05 | 0.94 | 1.10 | |
|
Exelixis, Inc.
|
|
28.00% | 814.323 | 0.00 | -4.97 | 7.18 | 6.64 | 96.98 | |
|
DRAXIS Health Inc. (USA)
|
|
23.00% | 248.169 | 149.67 | 27.22 | 3.15 | 2.21 | 2.25 | |
|
Vertex Pharmaceuticals Incorporated
|
|
20.00% | 3,651.037 | 0.00 | -8.73 | 18.35 | 16.44 | 13.46 | |
|
Phase Forward Incorporated
|
|
18.00% | 718.172 | 24.59 | 45.68 | 5.35 | 4.43 | 3.83 | |
|
VirtualScopics, Inc.
|
|
15.50% | 12.088 | 0.00 | n/a | 2.14 | n/a | 2.37 | |
|
NPS Pharmaceuticals, Inc.
|
|
6.20% | 190.982 | 0.00 | -8.46 | 2.21 | 2.79 | n/a | |
|
Monogram Biosciences, Inc.
|
|
6.00% | 152.980 | 0.00 | -8.29 | 3.54 | 2.38 | n/a | |
|
Alexandria Real Estate Equities, Inc.
|
|
3.90% | 3,127.466 | 39.64 | 16.40 | 7.72 | 7.20 | 2.08 | |
|
Unigene Laboratories
|
|
3.00% | 147.426 | 0.00 | -55.33 | 7.22 | 5.68 | n/a | |
|
Liberty Property Trust
|
|
1.90% | 3,190.846 | 19.36 | 11.24 | 4.57 | 4.41 | 1.74 | |
|
AstraZeneca plc (ADR)
|
|
n/a | 61,325.890 | 10.96 | 9.30 | 2.07 | 1.93 | n/a | |
|
Medco Health Solutions Inc.
|
|
n/a | 22,492.002 | 24.66 | 18.85 | 0.51 | 0.46 | n/a | |
| Target | |||||||||
|
Baxter International Inc.
|
|
n/a | 37,733.634 | 22.11 | 18.57 | 3.35 | 3.08 | 7.23 | |
|
Forest City Enterprises, Inc.
|
|
n/a | 3,858.195 | 73.60 | n/a | 2.98 | n/a | 3.97 | |
|
CDC Corporation
|
|
n/a | 460.926 | 0.00 | 17.30 | 1.20 | 1.13 | n/a | |
|
Cangene Corporation
|
|
n/a | 419.506 | 35.91 | n/a | 3.44 | n/a | 2.32 | |
|
Antigenics, Inc.
|
|
n/a | 141.469 | 0.00 | -3.17 | 25.47 | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Customers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
|
Government - United States
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Buyer | |||||||||
|
Wal-Mart Stores, Inc.
|
|
n/a | 215,122.510 | 16.90 | 16.16 | 0.57 | 0.54 | 4.43 | |
|
Bayer AG (ADR)
|
|
n/a | 62,484.951 | 8.63 | 16.14 | 1.36 | 1.47 | n/a | |
|
CVS Caremark Corporation
|
|
n/a | 58,159.469 | 22.17 | 16.40 | 0.76 | 0.66 | n/a | |
|
Target Corporation
|
|
n/a | 42,822.504 | 15.04 | 14.83 | 0.68 | 0.64 | 2.80 | |
|
Walgreen Company
|
|
n/a | 37,538.316 | 17.88 | 17.36 | 0.66 | 0.64 | 3.42 | |
|
Costco Wholesale Corporation
|
|
n/a | 28,789.928 | 24.27 | 22.44 | 0.42 | 0.41 | 3.22 | |
|
Medco Health Solutions Inc.
|
|
n/a | 22,492.002 | 24.66 | 18.85 | 0.51 | 0.46 | n/a | |
|
The Kroger Co.
|
|
n/a | 16,672.325 | 14.12 | 13.50 | 0.24 | 0.23 | 6.02 | |
|
Sears Holdings Corporation
|
|
n/a | 13,980.061 | 16.92 | 30.03 | 0.28 | 0.29 | 2.48 | |
|
Safeway Inc.
|
|
n/a | 12,667.857 | 14.26 | 12.84 | 0.30 | 0.29 | 2.95 | |
|
Shire plc (ADR)
|
|
n/a | 11,237.178 | 0.00 | 19.78 | 4.61 | 3.83 | n/a | |
|
Henry Schein, Inc.
|
|
n/a | 5,188.605 | 24.11 | 19.53 | 0.88 | 0.79 | 7.78 | |
|
Amylin Pharmaceuticals, Inc.
|
|
n/a | 4,372.970 | 0.00 | -15.97 | 5.60 | 4.37 | 7.91 | |
|
Rite Aid Corporation
|
|
n/a | 2,378.033 | 0.00 | -6.88 | 0.11 | 0.09 | n/a | |
|
United Therapeutics Corporation
|
|
n/a | 1,932.605 | 97.32 | 38.47 | 9.16 | 7.34 | 6.48 | |
|
Biovail Corporation (USA)
|
|
n/a | 1,797.025 | 9.19 | 8.32 | 2.13 | 2.39 | 3.17 | |
|
Grupo Casa Saba, S.A. (ADR)
|
|
n/a | 885.439 | 12.47 | n/a | 0.43 | n/a | 1.71 | |
|
ViroPharma Incorporated
|
|
n/a | 686.843 | 7.20 | 10.87 | 3.37 | 3.04 | 1.84 | |
|
Par Pharmaceutical Companies, Inc.
|
|
n/a | 591.924 | 11.86 | 22.97 | 0.77 | 0.94 | 1.75 | |
|
POZEN Inc.
|
|
n/a | 325.155 | 69.72 | -24.41 | 6.08 | 8.18 | 9.22 | |
|
Verenium Corporation
|
|
n/a | 250.530 | 0.00 | -3.72 | 5.41 | 3.68 | n/a | |
|
AVANT Immunotherapeutics, Inc.
|
|
n/a | 157.928 | 0.00 | -5.31 | 30.95 | 15.37 | n/a | |
| Target | |||||||||
|
Government - United Kingdom
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Government - United States
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Partners
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
|
Sanofi-Aventis SA (ADR)
|
|
n/a | 105,870.385 | 12.98 | 9.45 | 2.34 | 2.48 | n/a | |
|
Merck & Co., Inc.
|
|
n/a | 87,371.039 | 26.67 | 11.62 | 3.61 | 3.38 | 5.45 | |
|
Antigenics, Inc.
|
|
n/a | 141.469 | 0.00 | -3.17 | 25.47 | n/a | n/a | |
| Buyer | |||||||||
|
Roche Holding Ltd. (ADR)
|
|
n/a | 163,455.599 | 16.51 | 19.02 | 3.49 | 3.93 | 5.01 | |
|
Sanofi-Aventis SA (ADR)
|
|
n/a | 105,870.385 | 12.98 | 9.45 | 2.34 | 2.48 | n/a | |
|
Merck & Co., Inc.
|
|
n/a | 87,371.039 | 26.67 | 11.62 | 3.61 | 3.38 | 5.45 | |
|
Bayer AG (ADR)
|
|
n/a | 62,484.951 | 8.63 | 16.14 | 1.36 | 1.47 | n/a | |
|
AstraZeneca plc (ADR)
|
|
n/a | 61,325.890 | 10.96 | 9.30 | 2.07 | 1.93 | n/a | |
|
Gilead Sciences, Inc.
|
|
n/a | 48,179.585 | 29.83 | 26.91 | 11.39 | 9.42 | 13.92 | |
|
Celgene Corporation
|
|
n/a | 25,965.748 | 114.68 | 45.90 | 18.47 | 12.42 | 9.57 | |
|
Medco Health Solutions Inc.
|
|
n/a | 22,492.002 | 24.66 | 18.85 | 0.51 | 0.46 | n/a | |
|
Biogen Idec Inc.
|
|
n/a | 19,059.016 | 29.91 | 19.43 | 6.01 | 5.08 | 10.01 | |
|
Allergan, Inc.
|
|
n/a | 18,177.606 | 36.41 | 22.52 | 4.61 | 3.91 | 82.70 | |
|
Shire plc (ADR)
|
|
n/a | 11,237.178 | 0.00 | 19.78 | 4.61 | 3.83 | n/a | |
|
Eisai Co., Ltd (ADR)
|
|
n/a | 9,903.066 | 13.89 | 13.80 | 1.50 | 1.36 | 2.34 | |
|
Quest Diagnostics Incorporated
|
|
n/a | 8,981.337 | 26.42 | 14.93 | 1.34 | 1.24 | n/a | |
|
Sigma-Aldrich Corporation
|
|
n/a | 7,951.151 | 25.56 | 23.48 | 3.90 | 3.50 | 7.51 | |
|
Millennium Pharmaceuticals, Inc.
|
|
n/a | 5,249.579 | 351.82 | 62.88 | 9.95 | 8.92 | 7.29 | |
|
Henry Schein, Inc.
|
|
n/a | 5,188.605 | 24.11 | 19.53 | 0.88 | 0.79 | 7.78 | |
|
Illumina, Inc.
|
|
n/a | 4,379.171 | 0.00 | 68.48 | 11.94 | 8.34 | 35.08 | |
| Target | |||||||||
|
Sanofi-Aventis SA (ADR)
|
|
n/a | 105,870.385 | 12.98 | 9.45 | 2.34 | 2.48 | n/a | |
|
Merck & Co., Inc.
|
|
n/a | 87,371.039 | 26.67 | 11.62 | 3.61 | 3.38 | 5.45 | |
|
Baxter International Inc.
|
|
n/a | 37,733.634 | 22.11 | 18.57 | 3.35 | 3.08 | 7.23 | |
|
Cangene Corporation
|
|
n/a | 419.506 | 35.91 | n/a | 3.44 | n/a | 2.32 | |
|
Antigenics, Inc.
|
|
n/a | 141.469 | 0.00 | -3.17 | 25.47 | n/a | n/a | |
- Defined by the Company
- Defined by Others
Financials
| Buyer | Target | Combined Entity | |
|---|---|---|---|
| Income Statement | |||
| Operating Items | |||
| Revenue | 45,306.0 | 73.8 | 45,379.8 |
|
Other Revenue
|
0.0 | 0.0 | 0.0 |
| Total Revenue | 45,306.0 | 73.8 | 45,379.8 |
|
Cost of Revenue
|
10,604.5 | 45.7 | 10,650.2 |
|
SG&A Expense
|
13,869.4 | 29.5 | 13,898.9 |
|
Depreciation & Amortization
|
0.0 | 0.0 | 0.0 |
|
Research & Development
|
6,635.6 | 77.1 | 6,712.7 |
|
Interest Expense
|
0.0 | 0.0 | 0.0 |
|
Other Operating Expense
|
-947.4 | -29.5 | -976.8 |
| Total Expenses | 30,162.1 | 122.8 | 30,285.0 |
|
Operating Income
|
15,143.9 | -49.1 | 15,094.8 |
| Non Operating Items | |||
|
Interest Expense (Inc.), Net Non-Oprtng
|
-281.2 | 3.0 | -278.3 |
|
Other, Net
|
0.0 | 0.0 | 0.0 |
| Income Before Taxes | 14,862.7 | -45.1 | 14,817.6 |
| Income Taxes | 4,272.1 | 5.1 | 4,277.3 |
| Income After Taxes | 10,590.6 | -50.2 | 10,540.3 |
| Minority Interest (IS) | -191.5 | 0.0 | -191.5 |
|
Net Income - Excl. Xord. Items
|
10,399.1 | -50.2 | 10,348.9 |
|
Net Income - Incl. Xord. Items
|
10,399.1 | -50.2 | 10,348.9 |
|
Income Avail. to Common
|
10,399.1 | -50.2 | 10,348.9 |
| Share Items | |||
|
Basic Avg. Shares Outstanding
|
2,701.5 | 53.6 | 2,755.1 |
|
Basic EPS - Excl. Xord. Items
|
3.85 | n/a | 3.76 |
|
Basic EPS - Incl. Xord. Items
|
3.85 | n/a | 3.76 |
| Full Dilution Adjustment | 0.0 | 0.0 | 0.0 |
| Fully Diluted Shares Outstanding | 2,705.0 | 54.9 | 2,759.9 |
|
F.D. EPS - Excl. Xord. Items
|
3.84 | n/a | 3.75 |
|
F.D. EPS - Incl. Xord. Items
|
3.84 | n/a | 3.75 |
| Dividends Per Common Share | 2.11 | 0.00 | 2.11 |
| Balance Sheet | |||
| Assets | |||
|
Cash and Equivalents
|
6,739.3 | 71.4 | 6,810.7 |
|
ST Investments
|
3,247.0 | 19.8 | 3,266.8 |
|
Accounts Receivable
|
11,075.2 | 8.1 | 11,083.3 |
|
Inventory
|
6,107.0 | 5.9 | 6,113.0 |
|
Other Current Assets
|
8.0 | 1.4 | 9.4 |
|
Current Assets
|
27,176.4 | 106.6 | 27,283.1 |
|
Accum D&A
|
0.0 | 0.0 | 0.0 |
|
PPE, Net
|
15,598.6 | 31.3 | 15,629.9 |
| Goodwill & Intangibles | 11,619.7 | 26.1 | 11,645.8 |
| Long Term Investments | 1,689.3 | 1.2 | 1,690.5 |
| Other Assets | 0.0 | 0.0 | 0.0 |
|
Other LT Assets
|
5,750.0 | 0.6 | 5,750.6 |
| Total Assets | 61,834.1 | 165.7 | 61,999.8 |
| Liabilities | |||
| Accounts Payable | 9,695.0 | 4.2 | 9,699.2 |
| Payable/Accrued | 0.0 | 0.0 | 0.0 |
| Accrued Expenses | 0.0 | 12.3 | 12.3 |
|
ST Debt
|
6,988.6 | 15.6 | 7,004.2 |
| Other (Current) Liabilities | 3,949.0 | 4.9 | 3,954.0 |
|
Current Liab.
|
20,632.6 | 37.0 | 20,669.6 |
|
LT Debt
|
14,094.8 | 2.6 | 14,097.4 |
|
Total LT Debt
|
14,094.8 | 2.6 | 14,097.4 |
| Minority Interest (BS) | 612.3 | 0.0 | 612.3 |
| Deferred Taxes | 1,769.1 | 0.0 | 1,769.1 |
|
Other LT Liab.
|
5,572.5 | 0.6 | 5,573.1 |
|
Total Liabilities
|
42,681.3 | 40.2 | 42,721.5 |
| Shareholders Equity | |||
| Common Stock | 2,997.7 | 21.2 | 3,018.8 |
| Additional Paid in Capital | 2,525.0 | 193.8 | 2,718.8 |
| Retained Earnings | 13,630.1 | -89.4 | 13,540.7 |
| Other Equity | 0.0 | 0.0 | 0.0 |
|
Total Equity
|
19,152.8 | 125.6 | 19,278.4 |
|
Total Liab. & Equity
|
61,834.1 | 165.7 | 61,999.8 |
|
Shares Outstanding
|
3,006.3 | 53.6 | 3,059.9 |
| Cash Flow | |||
| Operating Cash Flow | |||
| CF Net Income | 10,590.6 | -45.1 | 10,545.5 |
| CF Depreciation | 1,587.6 | 10.3 | 1,597.9 |
| CF Amortization | 450.7 | 0.0 | 450.7 |
| CF Deferred Taxes | 0.0 | 0.0 | 0.0 |
| Other Non-Cash Items | 4,792.7 | -8.7 | 4,784.0 |
| Change in Working Capital | -5,133.7 | -24.7 | -5,158.5 |
| Total Cash From Operating Activities | 12,287.8 | -68.2 | 12,219.6 |
| Investing Cash Flow (not calculated) | |||
| Capital Expenditures | -4,274.1 | -3.0 | -4,277.1 |
| Other Investing Cash Flows | -1,727.2 | 17.8 | -1,709.4 |
| Total Cash From Investing Activities | -6,001.3 | 14.8 | -5,986.5 |
| Financing Cash Flow (not calculated) | |||
| Dividends Paid | -5,570.5 | 0.0 | -5,570.5 |
| Purchase Or Sale of Stock | -6,418.2 | -0.4 | -6,418.6 |
| Purchase and Retirement of Debt | 3,177.2 | 37.4 | 3,214.5 |
| Other Financing Cash Flow | -1,194.7 | -25.9 | -1,220.6 |
| Total Cash From Financing Activities | -3,472.3 | 4.0 | -3,468.4 |
| Exchange Rate Effects | 95.7 | 3.2 | 98.9 |
| Net Change in Cash | 2,909.9 | -46.3 | 2,863.6 |
| Cash Taxes Paid | 3,827.4 | -8.1 | 3,819.3 |
| Cash Interest Paid | 753.9 | 1.6 | 755.5 |